ClinicalTrials.gg
Enrolling by invitationNCT05593757QUEEN-IVFUpdated Sep 13, 2023

Quinidine Versus Verapamil in Short-coupled Idiopathic Ventricular Fibrillation

A Phase 2 interventional study of Quinidine and Verapamil in Short-coupled Idiopathic Ventricular Fibrillation, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Enrolling by invitation at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Ventricular Fibrillation with a site in Netherlands — 6 open to participants now, 6 under way, 1 of them phase 3. Ventricular Fibrillation · Netherlands.

Planned enrollment
11th of 11
24 · median 280
Started
2022
the only one that year
Phase 2
3 of 17
1 open now
Registered
13th of 17
by date
Lead sponsor
1 of 17
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Among the 17 studies in Ventricular Fibrillation with a site in Netherlands, this one is the 11th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 2, and was the 13th registered.

Ventricular Fibrillation

186 studies on the registry are indexed under Ventricular Fibrillation; 37 are open to participants now.

Browse Ventricular Fibrillation studies →

Open to participants now

6 of the 17 studies in Ventricular Fibrillation with a site in Netherlands are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 22 Ventricular Fibrillation studies recruiting now, 19 (86%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Ventricular Fibrillation with a site in Netherlands, or all of them as a file.
02

Study summary

Short-coupled idiopathic ventricular fibrillation (IVF) is a rare subtype of idiopathic ventricular fibrillation that is characterized by ventricular fibrillation (VF) or polymorphic ventricular tachycardia (PVT) initiated by a short-coupled premature ventricular contraction (PVC). Although patients are protected from sudden cardiac death by an implantable cardioverter-defibrillator (ICD), additional antiarrhythmic drug therapy is indispensable as recurrent ICD shocks are not uncommon and can negatively affect quality of life. Verapamil and quinidine have been suggested as effective antiarrhythmic drugs, but at present it is unknown whether these drugs reduce the incidence of arrhythmic events. This pilot study will provide insight into the advisability and feasibility of a randomized controlled trial (RCT) and provide data needed to determine the most appropriate design and the sample size.

03

Conditions studied

  • Short-coupled Idiopathic Ventricular Fibrillation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least one of the following 3 principal diagnostic criteria for short-coupled IVF:

    A. Diagnosis of short-coupled IVF, based on any documentation (i.e., , Holter monitor, device electrogram (EGM), or telemetry) of PVT of ≥3 consecutive beats or VF initiated by a PVC with a coupling interval \<350 ms B. Isolated PVCs with a coupling interval \<350 ms during the index admission after SCA based on a shockable rhythm or (presumed) arrhythmogenic syncope C. DPP6 haplotype carrier

  2. Functioning transvenous or subcutaneous ICD in place
  3. Sudden cardiac arrest, (near)syncope, appropriate ICD shock or nonsustained PVT documented by the ICD at least once in the past 2 years
  4. Genetic testing has been initiated. Results are not required to be known at the time of inclusion. In subjects who are family members of DPP6 carrying index patients, genes other than DPP6 are not required to be tested
  5. Willing to undergo two assigned treatment periods with verapamil and quinidine
  6. Age ≥ 18 years

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation
  • Current treatment with class 1 antiarrhythmic medication (other than quinidine), class 3 antiarrhythmic medication, or digoxin, unless this medication is discontinued; patients who are currently treated with amiodarone will not be included due to the long elimination half-life of amiodarone, unless amiodarone was only administered intravenously for a short period of time
  • Patients with a history of therapy ventricular arrhythmia on an adequate dose of verapamil or quinidine, as determined by the treating cardiologist.
  • to quinidine or verapamil (see section 7.6)
  • Significant structural heart disease ( \<50%, suspicion or definitive diagnosis of cardiomyopathy, moderate/severe pulmonary, mitral, or aortic valve stenosis or regurgitation)
  • Suspicion or definitive diagnosis of another (heritable) arrhythmia syndrome, e.g.

Brugada syndrome, early repolarization syndrome or catecholaminergic polymorphic ventricular tachycardia

  • Presence of a short (\<350 ms) or prolonged (>480 ms) heart-rate interval on the resting at baseline
  • Presence of a pathogenic or likely-pathogenic ryanodine receptor 2 (RYR2) mutation
  • Presence of ischemia-induced short-coupled ventricular arrhythmia in patient with documented coronary spasm
  • Presence of pause-dependent torsade de pointes [preceding R-R interval prior to the trigger PVC >1500 ms in individuals without pacemaker/ICD or >1300 ms in individuals with pacemaker/ICD] following a stable baseline rhythm. Initiation of ventricular arrhythmia by short-long-short cycles (R-R cycles \<1300 ms) with a short-coupled trigger PVC is allowed
  • Significant coronary artery disease (≥50% narrowing of the diameter of the lumen of the left main coronary artery or ≥70% narrowing of the diameter of the lumen of the left anterior descending coronary artery, left circumflex artery or right coronary artery)
  • Reversible metabolic or pharmacological/toxicological conditions that may cause electrophysiological findings similar to short-coupled IVF
  • Patients who are considered electrically unstable, at physician's discretion, due to active electrical storm or very frequent nonsustained episodes of short-coupled IVF requiring intravenous or invasive therapy
  • Successful radiofrequency ablation of the PVC initiating short-coupled IVF and absence of documented (non)sustained episodes of short-coupled PVT/VF afterwards. The patient will, however, be eligible to participate in the study if ≥ 1 episode of short-coupled PVT/VF is documented after the ablation procedure
  • Intention to perform radiofrequency ablation of the PVC initiating short-coupled IVF during the course of the study
  • Serious known comorbid disease with a of less than two years
  • Ongoing medical condition that is deemed by the principal investigator to interfere with the conduct or assessments of the study or safety of the subjects
  • Circumstances that prevent follow-up
  • Inability to take orally administered tablets
  • Inability to provide
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Quinidine in period A, verapamil in period B

    For this arm, patients will be treated with quinidine 200 mg thrice daily during period A. During period B, patients will be treated with verapamil 320-480mg daily during period B. The duration of the periods is different for each patient and depends on the time of inclusion.

    Drug: Quinidine · Drug: Verapamil

  • Experimental
    Verapamil in period A, quinidine in period B

    For this arm, patients will be treated with verapamil 320-480mg daily during period A. During period B, patients will be treated with quinidine 200 mg thrice daily during period A. The duration of the periods is different for each patient and depends on the time of inclusion.

    Drug: Quinidine · Drug: Verapamil

Interventions

06

What researchers measure

Primary outcomes

  1. Sustained ventricular arrhythmia

    Sustained ventricular arrhythmia, assessed using the severity scoring system. A subject will be scored in each treatment period according to the scoring system by the Endpoint Classification Committee. The highest applicable score will be used. Ventricular arrhythmia scoring system: 0= No arrhythmic events 1. A single arrhythmic event 2. Electrical storm (≥3 episodes of sustained PVT/VF within 24 hours) 3. ≥2, but \<5 arrhythmic events 4. ≥5 arrhythmic events

    Time frame: 3 years

Secondary outcomes

  1. Time to first arrhythmic event

    The time between the first day in each period and the first arrhythmic event in that period

    Time frame: 3 years

  2. Incidence of quinidine-induced torsade de pointes

    Time frame: 3 years

  3. Incidence of sustained monomorphic ventricular tachycardia

    Time frame: 3 years

  4. Number of inappropriate ICD shocks

    Time frame: 3 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Sep 2025, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2022
First posted
Oct 25, 2022
StartActual
Oct 1, 2022
Primary completionEst.
Sep 1, 2025
CompletionEst.
Oct 1, 2025
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05593757
Responsible party
Christian van der Werf (Principal Investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Oct 25, 2022
Start date
Oct 1, 2022
Primary completion
Sep 1, 2025 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
Sep 13, 2023

Study contacts

Christian van der Werf, MD PhD
principal investigator · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Quinidine · Verapamil

Start the discussion